Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase I for Follicular Thyroid Cancer. According to GlobalData, Phase I drugs for Follicular Thyroid Cancer have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cabozantinib s-malate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cabozantinib s-malate overview
Cabozantinib s-malate (XL184, BMS907351, Cometriq) is a s-malate salt form of cabozantinib. It is formulated as hard gelatin capsules for oral route of administration. Cometriq is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer.
It is under development for metastatic cervical cancer, metastatic castration-resistant prostate cancer (mCRPC), clear cell renal cell carcinoma, advanced or metastatic urothelial cancer, carcinoid tumor, gastroesophageal adenocarcinoma, metastatic melanoma, thyroid cancer, neuroendocrine gastroenteropancreatic tumors, thyroid cancer, hepatocellular carcinoma, pheochromocytoma, bladder cancer, paraganglioma (glomus jugulare tumor), metastatic uveal melanoma, neuroendocrine gastroenteropancreatic tumors (gep-net), breast cancer, hormone-receptor-positive breast cancer with bone metastases, transitional cell carcinoma (urothelial cell carcinoma), merkel cell carcinoma, bladder cancer, peritoneal cancer, fallopian tube cancer, epithelial ovarian cancer, endometrial cancer, urethral cancer, ureter cancer, rhabdomyosarcoma, non-rhabdomyosarcoma, Wilms' tumor (nephroblastoma), ewing sarcoma, osteosarcoma, transitional cell carcinoma (urothelial cell carcinoma), papillary renal cell carcinoma, recurrent head and neck cancer squamous cell carcinoma,squamous cell carcinoma, metastatic colorectal cancer, plexiform neurofibroma, penile cancer, metastatic adenocarcinoma of the pancreas, relapsed/refractory multiple myeloma, adenocarcinoma of the gastroesophageal junction, non-small cell lung cancer, esophageal cancer, castration-resistant prostate carcinoma [CRPC], small cell lung cancer [SCLC], recurrent or progressive meningioma, papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC) and triple-negative breast cancer [TNBC].
It was also under development for relapsed/refractory acute myeloid leukemia, anaplastic thyroid cancer, astrocytoma, glioblastoma multiforme, small-cell lung cancer, and renal failure.
Exelixis is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company’s pipeline product candidates include XL092 for the treatment of advanced solid malignancies and XL888, an ATP-competitive inhibitor of HSP90, and others. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.
For a complete picture of Cabozantinib s-malate’s drug-specific PTSR and LoA scores, buy the report here.